#Epclusa

The assurance arrives as the pharma giant cuts off most emergency access to remdesivir, a potential COVID-19 treatment.

Gilead Sciences’ direct-acting antiviral regimen was previously approved for adults.

Six weeks, compared with the standard 12 weeks, was associated with an unacceptably high rate of viral relapse.

A recent study found that providing opioid use disorder treatment was associated with a high hep C cure rate and less drug use.

There are a variety of hepatitis C treatments offered for all genotypes, with various stages of liver damage.

Treatment for hep C has improved greatly over the past decades, with medications that treat more than one virus strain at the same time.

The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.

The drug can quickly reverse opioid-driven overdoses.

Past research has found that proton pump inhibitors and histamine H2 agonists are associated with lower levels of certain hep C drugs.

A quick overview of our reporting on the 53rd International Liver Congress in Vienna

These drugs are approved to treat all six major genotypes of hepatitis C.

This from a real-world analysis of people treated for hep C in the United States.

The three-drug regimen beat the virus in nearly all those who had not been cured of hep C by previous treatment.

The subscription-based model is the first of its kind.

What’s more, such treatment is linked to remission of non–Hodgkin lymphoma.